Global Haemophilia Epidemiology and Patient Flow Analysis - 2016

Global Haemophilia Epidemiology and Patient Flow Analysis - 2016

  • January 2016 •
  • Report ID: 3895285 •
  • Format: PDF
Fore Pharma announced the results of its Haemophilia patient population study in a new report ‘Global Haemophilia Epidemiology and Patient Flow Analysis - 2016’. The report provides insights into Haemophilia epidemiology, Haemophilia diagnosed patients, and Haemophilia treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Haemophilia derived from epidemiological analysis, percentage of patients diagnosed with Haemophilia, and percentage of patients treated with Haemophilia therapy.

The study helps executives estimate Haemophilia market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Haemophilia prevalence, Haemophilia diagnosis rate, and Haemophilia treatment rate for the period 2015 - 2022. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on collection and interpretation of data from registries, scientific journals and literatures, government databases and other secondary sources.

Key Features of the Report:
- Haemophilia: Disease Definition
- Haemophilia Patient Flow
- Haemophilia Prevalence
- Haemophilia Diagnosed Patients
- Haemophilia Treated Patients